AR054237A1 - Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer - Google Patents

Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer

Info

Publication number
AR054237A1
AR054237A1 AR20060100918A ARP060100918A AR054237A1 AR 054237 A1 AR054237 A1 AR 054237A1 AR 20060100918 A AR20060100918 A AR 20060100918A AR P060100918 A ARP060100918 A AR P060100918A AR 054237 A1 AR054237 A1 AR 054237A1
Authority
AR
Argentina
Prior art keywords
antibody
indolinone
compound
cancer
ylidene
Prior art date
Application number
AR20060100918A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR054237A1 publication Critical patent/AR054237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

Administracion de un anticuerpo anti-CTLA4, particularmente a anticuerpos humanos contra CTLA4 humano, tales como aquellos que tienen las secuencias aminoacídicas de los anticuerpos 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (también designado como 11.2.1 o CP-675.206), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1 e ipilimumab (también designado como 10D1 o MDX-010), en combinacion con u inhibidor de receptor tirosina quinasa (RTKI) de indolinona, por ejemplo, N-[2- dietilamino]etil]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihidro-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida (compuesto 1), N-[2-etilamino]etil]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihidro-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida (compuesto 2) y 5-[(Z)-(5-fluoro-2-oxo-1,2-dihidro-3H-indol-3-iliden)metil]-N-[(2S)-2-hidroxi-3-morfolin-4-ilpropil]-2,4-dimetil-1H-pirrol-3-carboxamida (compuesto 3), para el tratamiento del cáncer. Se refiere a administrar una combinacion de un anticuerpo anti-CTLA4 y un RTKI de indolinona tal como, entre otros, compuesto 1. Se refiere a la terapia neocoadyuvante, coadyuvante, de primera línea, de segunda línea y de tercera línea del cáncer, tanto localizado como metastatizado, en cualquier punto a lo largo del espectro continuo de la enfermedad (por ejemplo, en cualquier etapa del cáncer). Reivindicacion 23: Una composicion farmacéutica para el tratamiento del cáncer, comprendiendo dicha composicion una cantidad terapéuticamente eficaz de un anticuerpo anti-CTLA4, o porcion de union a antígeno del mismo, y una cantidad terapéuticamente eficaz de un RTKI de indolinona, y un vehículo farmacéuticamente aceptable.
AR20060100918A 2005-03-23 2006-03-10 Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer AR054237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66465305P 2005-03-23 2005-03-23

Publications (1)

Publication Number Publication Date
AR054237A1 true AR054237A1 (es) 2007-06-13

Family

ID=36680342

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060100918A AR054237A1 (es) 2005-03-23 2006-03-10 Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer

Country Status (16)

Country Link
US (1) US20090074787A1 (es)
EP (1) EP1863532A1 (es)
JP (1) JP2006265245A (es)
KR (1) KR20070104673A (es)
CN (1) CN101146553A (es)
AR (1) AR054237A1 (es)
AU (1) AU2006227880A1 (es)
BR (1) BRPI0607579A2 (es)
CA (1) CA2602316A1 (es)
IL (1) IL185491A0 (es)
MX (1) MX2007011767A (es)
NZ (1) NZ561138A (es)
RU (1) RU2007135167A (es)
TW (1) TW200700083A (es)
WO (1) WO2006101692A1 (es)
ZA (1) ZA200708026B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034327A1 (en) * 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
AU2007339762B2 (en) * 2006-12-27 2011-03-31 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
ES2768990T3 (es) * 2009-07-20 2020-06-24 Bristol Myers Squibb Co Combinación de anticuerpos anti-CTLA4 con gemcitabina para el tratamiento sinérgico de enfermedades proliferativas
WO2011045704A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JP6322413B2 (ja) 2011-03-10 2018-05-09 プロヴェクタス ファーマテック，インク． 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US10094835B2 (en) * 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US11219672B2 (en) * 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
AU2016219170B2 (en) * 2015-02-13 2021-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CTLA4
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
CN114344462A (zh) 2015-06-24 2022-04-15 英摩杜伦治疗学公司 用于癌症治疗的检查点抑制剂和全细胞分枝杆菌
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
AU2017414149A1 (en) 2017-05-19 2019-11-07 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
CA3093036A1 (en) * 2018-03-07 2019-09-12 Pfizer Inc. Anti-pd-1 antibody compositions
CN112673092B (zh) 2018-07-11 2024-03-29 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
KR102371980B1 (ko) 2020-06-29 2022-03-08 인하대학교 산학협력단 췌장암 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ATE369359T1 (de) * 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
WO2002096361A2 (en) * 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
EP1549678A4 (en) * 2002-09-30 2006-01-18 Pfizer Prod Inc HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
BRPI0415022A (pt) * 2003-10-02 2006-11-28 Pharmacia & Upjohn Co Llc sais e polimorfos de um composto de indolinona substituìda com pirrol
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
WO2005092380A2 (en) * 2004-03-26 2005-10-06 Pfizer Products Inc Uses of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
NZ561138A (en) 2009-06-26
AU2006227880A1 (en) 2006-09-28
BRPI0607579A2 (pt) 2009-09-15
CA2602316A1 (en) 2006-09-28
EP1863532A1 (en) 2007-12-12
JP2006265245A (ja) 2006-10-05
CN101146553A (zh) 2008-03-19
IL185491A0 (en) 2008-01-06
US20090074787A1 (en) 2009-03-19
ZA200708026B (en) 2008-11-26
WO2006101692A1 (en) 2006-09-28
TW200700083A (en) 2007-01-01
RU2007135167A (ru) 2009-03-27
MX2007011767A (es) 2007-10-18
KR20070104673A (ko) 2007-10-26

Similar Documents

Publication Publication Date Title
AR054237A1 (es) Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
US20230149502A1 (en) Conjugate of a tubulysin analog with branched linkers
US20190367453A1 (en) Conjugates of cell binding molecules with cytotoxic agents
ES2701076T3 (es) Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
US20210169896A1 (en) A cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
US20230241241A1 (en) Conjugates of a cell-binding molecule with camptothecin analogs
JP2006265245A5 (es)
WO2020258893A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
AU2019426942B2 (en) A conjugate of an amanita toxin with branched linkers
Cui et al. Targeting aminopeptidase N (APN/CD13) with cyclic-imide peptidomimetics derivative CIP-13F inhibits the growth of human ovarian carcinoma cells
AR048502A1 (es) Sinergia terapeutica de compuestos anti-cancer
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
IL257355A (en) Selection of patients for combination therapy
AR069682A1 (es) Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)
EP3057614A1 (en) Combination therapies with psma ligand conjugates
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
WO2003061571A3 (en) Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
US20190060473A1 (en) Hsp90 inhibitor drug conjugates
WO2017050240A1 (en) Method to treat cancer using arginine delpetor and ornithine decarboxylase (odc) inhibitor
CA2860473A1 (en) Combination therapy for the treatment of cancer
AR062215A1 (es) Inhibidor de trombina activo por via oral

Legal Events

Date Code Title Description
FB Suspension of granting procedure